Operating Efficiencies
Recent cGMP facility enables manufacturing of solid dosage materials and supplies for early stage clinical studies
- Focus on EMISPHEREŽ delivery agent performance, safety and scale up
- Leverage more early stage programs for outlicensing
Improved productivity in carrier production and scale up
- Cycle time reduced; moving more compounds through the technical concept stage
- Synthesis and screening of delivery agents (Total 2002 = 250; As of 9/03 = 300)